TAK-771-4002: Evaluating the Safety of GAMMAGARD LIQUID for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

First published 11/03/2022

Last updated 02/07/2024

EU PAS number:

EUPAS46101

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

TAK-771-4002-protocol-original_redact

English (1.52 MB - PDF)View document

Study results

Study results

TAK-771-4002-clinical-study-report-redact

English (1.38 MB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents